Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced ...

SYMBRAVO, which combines meloxicam and rizatriptan, targets multiple pathways underlying a migraine attack. Clinical trials have shown that a single dose can provide rapid pain relief and return ...

Axsome Therapeutics (AXSM) announced that the EMERGE Phase 3 trial of SYMBRAVO in patients experiencing inadequate response to oral CGRP inhibitors met its primary endpoint, with SYMBRAVO ...

The adjustment follows the recent approval of Axsome's migraine treatment, Symbravo (AXS-07), which has been met with positive reception and is predicted to have a strong commercial future.

Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. Per the company ...

In January 2025, the FDA approved Axsome’s Symbravo (meloxicam and rizatriptan) or AXS-07 for the acute treatment of migraine with or without aura in adults. The company expects to launch ...

On January 30, 2025, the U.S. Food and Drug Administration (FDA) approved Symbravo for the acute treatment of migraine with or without aura in adults. Symbravo represents a novel, multi ...

Findings showed meloxicam/rizatriptan statistically significantly improved migraine treatment response compared with prior oral CGRP inhibitor treatment. Topline data were announced from a phase 3 ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

47.9% of patients reported sustained pain relief for 24 hours with Symbravo, compared to 16.7% with oral CGRP inhibitors. In the trial, Symbravo rapidly and substantially improved migraine pain ...

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP ...